home / stock / redif / redif quote
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.67 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:29:59 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 90 | 02-07-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-31-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-30-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-29-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-28-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-27-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 90 | 01-24-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-23-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-22-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-21-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-20-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-17-2020 |
$ | $N/A | $0.67 | $N/A | $N/A | 0 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd Ord Company Name:
REDIF Stock Symbol:
OTCMKTS Market:
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Canada NewsWire RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation...
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty b...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Canada NewsWire - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107...